Additionally, NOL4 gene is a biomarker candidate of many CT antigens for diagnosis and prognosis of prostate cancer [33] and is a new potential therapeutic target in glioblastoma stem cells [34]. This evidence concerns the gene NOL4 and prostate carcinoma.